Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290153 | 0.87 | LPL (0.51) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL30693896 | 0.86 | LPL (0.44) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL239104 | 0.85 | LPL (0.56) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL30993446 | 0.82 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL189992 | 0.82 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL17491867 | 0.81 | LPL (0.53) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL2640296 | 0.81 | LPL (0.53) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL59540 | 0.81 | LPL (0.47) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL2130844 | 0.80 | LPL (0.51) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL16655624 | 0.80 | LPL (0.43) | LPLLIPGROCK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| EP-4719609-A1 | POLYMORPHS OF NEK 7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12551580-B2 | Heterocyclic compounds and imaging agents for imaging Huntington protein | CHDI FOUNDATION, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2025-12-23 | — | — | US | disclosed |
| WO-2007147574-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | LPL 3280/4885LIPG 2348/4885ROCK1 4288/4885 |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | LPL 4308/4885LIPG 3489/4885ROCK1 505/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | LPL 4298/4885LIPG 3401/4885ROCK1 393/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | LPL 4355/4885LIPG 4527/4885ROCK1 1036/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | LPL 635/4885LIPG 1013/4885ROCK1 4501/4885 |
| US-12551580-B2 | Heterocyclic compounds and imaging agents for imaging Huntington protein | HTT, HYPK, HIRA | LPL 3149/4885LIPG 4597/4885ROCK1 3190/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | LPL 4001/4885LIPG 4589/4885ROCK1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.